+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), Application (Oncology, Cardiology) - Global Forecast to 2024

  • ID: 4969113
  • Report
  • January 2020
  • Region: Global
  • 231 Pages
  • Markets and Markets
1 of 6
The nuclear medicine market is projected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period.

FEATURED COMPANIES

  • Bayer
  • Bracco Imaging
  • Cardinal Health
  • Curium
  • Eckert & Ziegler
  • Lantheus Medical Imaging
  • MORE

The nuclear medicine market is projected to grow at a CAGR of 4.7%

The nuclear medicine market is projected to reach USD 5.2 billion by 2024 from an estimated USD 4.1 billion in 2019, growing at a CAGR of 4.7% during the forecast period. The key factors propelling the growth of this market are the increasing incidence and prevalence of cancer & cardiovascular diseases and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices have made it difficult for a section of end-users to depend on nuclear medicine. These factors are expected to hamper the growth of the nuclear medicine market during the forecast period.

The Technetium-99m segment to hold the largest share of SPECT radiopharmaceuticals market in 2019

Based on type, the SPECT radiopharmaceuticals market is segmented Tc-99m, Tl-201, Ga-67, I-123, and other isotopes. In 2019, the Tc-99m segment is expected to command the largest share of the SPECT radiopharmaceuticals market. The large share of this segment can be attributed to the fact that Tc-99m is the most commonly used diagnostic radioisotope, which is used in around 80–90% of diagnostic scans and around 30 million patient examinations every year.

In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market

On the basis of indication, the therapeutic nuclear medicine applications market is segmented into thyroid indications, bone metastasis, lymphoma, endocrine tumors, and other indications. In 2018, the thyroid indications segment accounted for the largest share of the therapeutics market. On the other hand, the endocrine tumors segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment is majorly driven by the increasing use of therapeutic radiopharmaceuticals in the treatment of endocrine tumors.

The Asia Pacific to witness the highest growth during the forecast period

Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2019–2024. The major factors driving the growth of the Asia Pacific market include research initiatives in Japan, rising installations of PET scanners in India and China, and initiatives by the Australian government.

Break of primary participants was as mentioned below:

  • By Company Type: Tier I: 55%, Tier II: 25%, Tier III: 20%
  • By Designation: C-Level Executives: 35%, Directors: 25%, Others: 40%
  • By Region: North America: 20%, Europe: 25%, Asia Pacific : 40%, RoW: 15%.

Cardinal Health (US), GE Healthcare (US), and Curium (France) were the leading players in the nuclear medicine market.

Research Coverage:

This report studies the nuclear medicine market based on type, application, procedural volume assessment, and region. The report also studies the different factors (such as drivers, restraints, and opportunities) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report:

This report focuses on various levels of analysis - industry trends, market shares of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the nuclear medicine market, and their drivers, restraints, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the nuclear medicine market.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Bayer
  • Bracco Imaging
  • Cardinal Health
  • Curium
  • Eckert & Ziegler
  • Lantheus Medical Imaging
  • MORE

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Key Insights From Primary Sources
2.3 Market Size Estimation Methodology
2.4 Market Data Validation and Triangulation
2.5 Assumptions for the Study

3 Executive Summary

4 Premium Insights
4.1 Nuclear Medicine: Market Overview
4.2 Geographic Analysis: Nuclear Medicine Market for PET Applications, By Type (2017)
4.3 Nuclear Medicine Market Share, By Type, 2018 vs. 2023
4.4 Geographical Snapshot of the Nuclear Medicine Market

5 Market Overview
5.1.1 Introduction
5.1.2 Market Dynamics
5.1.3 Drivers
5.1.3.1 Increasing Incidence and Prevalence of Target Conditions
5.1.3.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
5.1.3.3 Initiatives to Lessen the Demand-Supply Gap of Mo-99
5.1.4 Restraints
5.1.4.1 Short Half-Life of Radiopharmaceuticals
5.1.5 Opportunities
5.1.5.1 Use of Radiopharmaceuticals in Neurological Applications
5.1.6 Challenges
5.1.6.1 Hospital Budget Cuts and High Equipment Prices

6 Nuclear Medicine/Radiopharmaceuticals Market,  By Type
6.1 Introduction
6.2 Diagnostic Nuclear Medicine
6.2.1 Spect Radiopharmaceuticals
6.2.1.1 TC-99m
6.2.1.2 TL-201
6.2.1.3 GA-67
6.2.1.4 I-123
6.2.1.5 Other Spect Isotopes
6.2.2 PET Radiopharmaceuticals
6.2.2.1 F-18
6.2.2.2 RU-82
6.2.2.3 Other PET Isotopes
6.3 Therapeutic Nuclear Medicine
6.3.1 Alpha Emitters
6.3.1.1 Ra-223
6.3.2 Beta Emitters
6.3.2.1 I-131
6.3.2.2 Y-90
6.3.2.3 SM-153
6.3.2.4 RE-186
6.3.2.5 LU-177
6.3.2.6 Other Beta Emitters
6.3.3 Brachytherapy Isotopes
6.3.3.1 I-125
6.3.3.2 IR-192
6.3.3.3 PD-103
6.3.3.4 CS-131
6.3.3.5 Other Brachytherapy Isotopes

7 Nuclear Medicine/Radiopharmaceuticals Market,By Application
7.1 Introduction
7.2 Diagnostic Applications
7.2.1 Spect Applications
7.2.1.1 Cardiology
7.2.1.2 Bone Scans
7.2.1.3 Thyroid
7.2.1.4 Pulmonary
7.2.1.5 Other Spect Applications
7.2.2 PET Applications
7.2.2.1 Oncology
7.2.2.2 Cardiology
7.2.2.3 Neurology
7.2.2.4 Other PET Applications
7.3 Therapeutic Applications
7.3.1 Thyroid
7.3.2 Bone Metastasis
7.3.3 Lymphoma
7.3.4 Endocrine Tumors
7.3.5 Other Therapeutic Applications

8 Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume
8.1 Introduction
8.2 Diagnostic Procedures
8.2.1 Spect Radiopharmaceuticals
8.2.2 PET Radiopharmaceuticals
8.3 Therapeutic Procedures
8.3.1 Beta Emitters
8.3.2 Alpha Emitters
8.3.3 Brachytherapy Isotopes

9 Nuclear Medicine/Radiopharmaceuticals Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 UK
9.3.4 Italy
9.3.5 Spain
9.3.6 Roe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 RoAPAC
9.5 Rest of the World

10 Competitive Landscape
 10.1 Overview
 10.2 Market Share Analysis
 10.3 Competitive Scenario
 10.3.1 Agreements, Partnerships, and Contracts
 10.3.2 Product Approvals
 10.3.3 Funding
 10.3.4 Acquisitions
 10.3.5 Expansions
 10.3.6 Other Developments

11 Company Profiles
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
 11.1 Cardinal Health
 11.2 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
 11.3 Curium
 11.4 Lantheus Medical Imaging
 11.5 Bayer
 11.6 Bracco Imaging
 11.7 Eczacibasi-Monrol Nuclear Products
 11.8 Nordion (A Subsidiary of Sterigenics International)
 11.9 Advanced Accelerator Applications  (Aaa, Acquired By Novartis)
 11.10 NTP Radioisotopes Soc, Ltd
 11.11 Joint Stock Company Isotope (JSC Isotope)
 11.12 Northstar Medical Radioisotopes, LLC
 11.13 Eckert & Ziegler
 11.14 Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma)
 11.15 Pharmalogic
 11.16 Institute of Isotopes Co., Ltd
 11.17 Sinotau Pharmaceuticals Group)
 11.18 Isotopia Molecular Imaging Limited
 11.19 Shine Medical Technologies
 11.20 Global Medical Solutions, Ltd
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix
 12.1 Discussion Guide
 12.2 Introducing Rt: Real-Time Market Intelligence
 12.3 Available Customizations
 12.4 Related Reports
 12.5 Author Details

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
5 of 6
  • Advanced Accelerator Applications  (Aaa, Acquired By Novartis)
  • Bayer
  • Bracco Imaging
  • Cardinal Health
  • Curium
  • Eckert & Ziegler
  • Eczacibasi-Monrol Nuclear Products
  • GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
  • Global Medical Solutions, Ltd
  • Institute of Isotopes Co., Ltd
  • Isotopia Molecular Imaging Limited
  • Joint Stock Company Isotope (JSC Isotope)
  • Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma)
  • Lantheus Medical Imaging
  • NTP Radioisotopes Soc, Ltd
  • Nordion (A Subsidiary of Sterigenics International)
  • Northstar Medical Radioisotopes, LLC
  • Pharmalogic
  • Shine Medical Technologies
  • Sinotau Pharmaceuticals Group)
Note: Product cover images may vary from those shown
6 of 6

Loading
LOADING...

Adroll
adroll